Haleon PLC Sponsored ADR (HLN) has released an update.
Haleon plc has updated its £10 billion Euro Medium Term Note Programme, with a recently published base prospectus, as part of its routine annual financial activities. The company, a global leader in consumer health products such as Advil and Sensodyne, has made the prospectus available for public viewing on their website. The document details are specifically intended for residents of certain countries and are not meant for general global distribution.
For further insights into HLN stock, check out TipRanks’ Stock Analysis page.
